Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Castration Resistant Prostate Cancer × tildrakizumab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer 1

Interventions

enzalutamide 9 Abiraterone Acetate 5 Prednisone 2 tildrakizumab 1 sabizabulin 1 rucaparib 1 pembrolizumab 1 fluzoparib 1 apatinib 1 abiraterone 1 Pluvicto 1 N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1 Docetaxel 1 Blood Specimen Collection 1 Biopsy 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡